Synapse - Maura Dickler

Results (263)

Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence

Journal Article

Yang, C.; Li, Z.; Bhatt, T.; Dickler, M.; Giri, D.; Scaltriti, M.; Baselga, J.; Rosen, N.; Chandarlapaty, S.
Oncogene (2017)

Fulltext@MSK | Save

The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis

Meeting Abstract

Turashvili, G.; Brogi, E.; Morrow, M.; Wiszowaty, A.; Dickler, M.; Norton, L.; Hudis, C.; Wen, H. Y.
Modern Pathology (2017)

Fulltext@MSK | Save

Breast carcinoma with recurrence score lower than 18: Rate of locoregional recurrence in a large series with clinical follow-up

Meeting Abstract

Turashvili, G.; Brogi, E.; Morrow, M.; Wiszowaty, A.; Dickler, M.; Norton, L.; Hudis, C.; Wen, H. Y.
Modern Pathology (2017)

Fulltext@MSK | Save

Breast carcinoma with 21-gene recurrence score lower than 18: Rate of distant metastases in a large series with clinical follow-up

Meeting Abstract

Wen, H. Y.; Krystel-Whittemore, M.; Patil, S.; Pareja, F.; Bowser, Z. L.; Dickler, M.; Norton, L.; Morrow, M.; Hudis, C.; Brogi, E.
Cancer Research (2017)

Fulltext@MSK | Save

A phase 2 study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC)

Meeting Abstract

Rugo, H.; Tolaney, S.; Dickler, M.; Kabos, P.; Ho, C. L.; Wildiers, H.; Jerusalem, G.; Ales-Martinez, J. E.; Hossain, A.; Johnston, E.; more...
Cancer Research (2017)

Fulltext@MSK | Save

Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy

Meeting Abstract

Iyengar, N. M.; Smyth, L.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S.; more...
Cancer Research (2017)

Fulltext@MSK | Save

Phase II study of taselisib (GDC-0032) plus fulvestrant in HER2-negative, hormone receptor-positive advanced breast cancer: Analysis by PIK3CA and ESR1 mutation status from circulating tumor DNA